Prostaglandylinositol cyclic phosphate (cPIP): A novel second messenger of insulin action. Comparative analysis of two kinds of 'insulin mediators'

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 4, 2001, Pages 273-284

  Shashkin, Pavel N ^a,c   Wasner, Heinrich K ^b   Ortmeyer, Heidi K ^a   Hansen, Barbara C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cyclo oxygenase; Inositolphosphoglycan; Insulin action; IRS 1; Macaca mulatta; Phospholipase A2; Phospholipase C; Prostaglandylinositol cyclic phosphate; Rhesus monkey

Indexed keywords

CELL PROTEIN; GLUCOCORTICOID; GLUCOSE; GLYCAN DERIVATIVE; INOSITOLPHOSPHOGLYCAN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDYLINOSITOL CYCLIC PHOSPHATE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOSYNTHESIS; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; EMBRYOPATHY; ENZYME ACTIVITY; GLUCOSE CLAMP TECHNIQUE; HORMONE ACTION; HYPERINSULINEMIA; IN VIVO STUDY; INSULIN RESISTANCE; LIVER; MEDIATOR; MOLECULAR WEIGHT; MONKEY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; CARBON-OXYGEN LIGASES; HUMANS; INOSITOL PHOSPHATES; INSULIN; PHOSPHOLIPASE C; PHOSPHOLIPASES A; PHOSPHOPROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; RECEPTOR, INSULIN; SECOND MESSENGER SYSTEMS;

EID: 0034851515     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.218     Document Type: Review

References (127)

1. The paradoxical regulation of protein phosphorylation in insulin action
2. Diverse signaling pathways in the cellular actions of insulin
3. Selective action of N-ethylmaleimide on insulin stimulation of metabolism in the surviving diaphragm
4. UDPglucose: Apha-1,4-glucan alpha-4-glucosyltransferase in heart regulation of the activity of the transferase in vivo and in vitro in rat. A dissociation in the action of insulin on transport and on transferase conversion
5. Stimulation of glycogen synthesis by insulin in human erythroleukemia cells requires the synthesis of glycosylphosphatidylinositol
6. Insulin mediators and the mechanism of insulin action
7. In search of a second messenger for insulin
8. Second messengers of insulin action
9. A role for inositol-glycan mediators and G-proteins in insulin action
10. Insulin second messengers
11. Identification of a novel inositol glycan signaling pathway with significant therapeutic relevance to insulin resistance: An insulin signaling model using both tyrosine kinase and G-proteins
12. Insulin increases near-membrane but not global Ca2+ in isolated skeletal muscle
13. Preparation and characterization of putative insulin mediators from liver
14. Pyruvate dehydrogenase activation in adipocyte mitochondria by an insulin-generated mediator from muscle
15. Insulin-stimulated diacylglycerol production results from the hydrolysis of a novel phosphatidylinositol glycan
16. Regulation of protein kinase and phosphoprotein phosphatase by cyclic AMP and cyclic AMP antagonist
17. Prostaglandyl-inositol cyclic-phosphate, a new second messenger
18. The endogenous cyclic AMP antagonist, cyclic PIP: Its ubiquity, hormone-stimulated synthesis and identification as prostaglandylinositol cyclic phosphate
19. Isolation of a post-binding inhibitor of insulin action from the sera of non-insulin-dependent diabetics
20. Insulin mediators in man: Effects of glucose ingestion and insulin resistance
21. Transport in isolated rat hepatocytes of the phospho-oligosaccharide that mimics insulin action. Effects of adrenalectomy and glucocorticoid treatment
22. Signalling pathways of an insulin-mimetic phosphoinositolglycan-peptide in muscle and adipose tissue
23. Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes
24. Cellular mechanisms of insulin resistance
25. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients
26. Insulin signaling in human skeletal muscle: Time course and effect of exercise
27. Regulation of glycogen synthase in rat hepatocytes. Evidence for multiple signaling pathways
28. Signaling pathways in insulin action: Molecular targets of insulin resistance
29. Diabetes and the role of inositol-containing lipids in insulin signaling
30. Inositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: Evidence for a significant regulatory role in preeclampsia at placental and systemic levels
31. Two different mechanisms for activation of cyclic PIP synthase: By a G protein or by protein tyrosine phosphorylation
32. Prostaglandylinositol cyclic phosphate synthase activity in the liver of insulin-resistant rhesus monkeys
33. Duality in the mechanism of action of insulin
34. Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes
35. Mass-spectrometric identification of prostaglandylinositol; the dephosphorylated cyclic AMP antagonist, cyclic PIP
36. Insulin resistance, a result of reduced synthesis of prostaglandylinositol cyclic phosphate, a mediator of insulin action? Regulation of cyclic PIP synthetase activity by oral antidiabetic and antihypertensive drugs
37. Eicosanoid production and phospholipase A2 activity in uterine tissue from castrated rats with non-insulin dependent diabetes mellitus
38. High glucose levels modulate eicosanoid production in uterine and placental tissue from non-insulin-dependent diabetic rats during late pregnancy
39. Dietary myoinositol therapy in hyperglycemia-induced embryopathy
40. Multifactorial basis of the syndrome of diabetic embryopathy
41. Abnormal metabolism of polyunsaturated fatty acids and phospholipids in diabetic glomeruli
42. Mechanism of decreased arachidonic acid in the renal cortex of rats with diabetes mellitus
43. Effects of green tea catechin on hepatic microsomal phospholipase A2 activities and changes of hepatic phospholipid species in streptozotocin-induced diabetic rats
44. Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus. A defect in the early steps of prostaglandin synthesis?
45. Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats
46. Increased muscular phospholipase A2 activity in diabetic rats
47. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats
48. An effect of prostagland in E, on glucose metabolism in rat adipose tissue
49. Effects of insulin and prior exercise on prostaglandin release from perfused rat muscle. Evidence that prostaglandins do not mediate changes in glucose uptake
50. Inhibitors of phospholipase A2 block the stimulation of protein synthesis by insulin in L6 myoblasts
51. The cyclo-oxygenase inhibitors indomethacin and ibuprofen inhibit the insulin-induced stimulation of ribosomal RNA synthesis in L6 myoblasts
52. Modulation of prostaglandin E2 synthesis in rat skeletal muscle
53. Influence of nitric oxide synthase and kinin antagonists on metabolic parameters in chronic streptozotocin-induced diabetes mellitus
54. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation
55. Diabetes mellitus affects prostaglandin E2 levels in mouse embryos during neurulation
56. Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment
57. Cross-talk between phospholipase C and phosphoinositide 3-kinase signalling pathways
58. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes
59. Effect of insulin and insulin-like growth factors I and II on phosphatidylinositol and phosphatidylinositol 4,5-bisphosphate breakdown in liver from humans with and without type II diabetes
60. Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDM
61. Platelet phosphoinositide turnover in streptozotocin-induced diabetes
62. Alteration of cholecystokinin-mediated phosphatidylinositol hydrolysis in pancreatic acini from insulin-deficient rats. Evidence for defective G protein activation
63. PtdIns-3,4,5-P3: A regulatory nexus between tyrosine kinases and sustained calcium signals
64. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling
65. Thrombin receptors modulate insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate accumulation in 1321N1 astrocytoma cells
66. Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate
67. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting
68. Phosphoinositide 3-kinase regulates phospholipase C gamma-mediated calcium signaling
69. Insulin receptor substrate 1 is required for insulin-mediated mitogenic signal transduction
70. 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice
71. The IRS-signalling system during insulin and cytokine action
72. The IRS-signalling system: A network of docking proteins that mediate insulin action
73. Disruption of IRS-2 causes type 2 diabetes in mice
74. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse
75. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus
76. Insulin signaling and action in fat cells: Associations with insulin resistance and type 2 diabetes
77. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM
78. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects
79. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance
80. Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4 knockout mice
81. Molecular mechanisms of insulin action in normal and insulin-resistant states
82. Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes
83. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling
84. Expression of variant forms of insulin receptor substrate-1 identified in patients with non-insulin-dependent diabetes mellitus
85. Insulin sensitivity is not affected by mutation of codon 972 of the human IRS-1 gene
86. Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes
87. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: The Atherosclerosis Risk in Communities Study
88. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle
89. Primate animal models of type 2 diabetes
90. Role of the insulin receptor C-terminal acidic domain in the modulation of the receptor kinase by polybasic effectors
91. Glomerular epithelial cell, polyanion neutralization is associated with enhanced prostanoid production
92. Insulin regulates liver glycogen synthase and glycogen phosphorylase activity reciprocally in rhesus monkeys
93. Insulin increases liver protein phosphatase-1 and protein phosphatase-2C activities in lean, young adult rhesus monkeys
94. Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenaline- or insulin-stimulation. Isolation, purification and prostaglandin E-requirement for its synthesis
95. Liver microsomal glucose-6-phosphatase is competitively inhibited by the lipid products of phosphatidylinositol 3-kinase
96. Adenosine 3′,5′-monophosphate-dependent protein kinase activity decreases in human muscle after insulin infusion
97. Insulin decreases skeletal muscle cAMP-dependent protein kinase (PKA) activity in normal monkeys and increases PKA activity in insulin-resistant rhesus monkeys
98. Polyunsaturated fatty acids, membrane function and metabolic diseases such as diabetes and obesity
99. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids
100. Skeletal muscle membrane lipids and insulin resistance
101. Dietary lipid profile is a determinant of tissue phospholipid fatty acid composition and rate of weight gain in rats
102. Dietary fats, membrane phospholipids and obesity
103. Dietary fats and insulin action
104. Relationships between the fatty acid composition of muscle and erythrocyte membrane phospholipid in young children and the effect of type of infant feeding
105. Mechanisms of dexamethasone-induced insulin resistance in healthy humans
106. Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486
107. Effects of glucocorticoids and sympathomimetic agents on basal and insulin-stimulated glucose metabolism
108. Can the diabetogenic effect of cortisol be explained by inhibition of cPIP synthase?
109. Myoinositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos
110. PGE2 prevents anomalies induced by hyperglycemia or diabetic serum in mouse embryos
111. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin
112. Insulin stimulates phospholipase D-dependent phosphatidylcholine hydrolysis, Rho translocation, de novo phospholipid synthesis, and diacylglycerol/protein kinase C signaling in L6 myotubes
113. Phospholipase C mimics insulin action on pyruvate dehydrogenase and insulin mediator generation but not glucose transport or utilization
114. Effects of insulin and phospholipase C in control and denervated rat skeletal muscle
115. Insulin action impaired by deficiency of the G-protein subunit G ialpha2
116. The role of G proteins in insulin signalling
117. Effect of insulin on SN-1,2-diacylglycerol species and de novo synthesis in rat skeletal muscle
118. Insulin increases a biochemically distinct pool of diacylglycerol in the rat soleus muscle
119. Insulin-dependent release of 5′-nucleotidase and alkaline phosphatase from liver plasma membranes
120. Insulin increases distinct species of 1,2-diacylglycerol in isolated perfused rat heart
121. Anti-inositolglycan antibodies selectively block some of the actions of insulin in intact BC3H1 cells
122. Studies on the possible involvement of prostaglandins in insulin generation of pyruvate dehydrogenase activator
123. An inositol phosphoglycan stimulates glycolysis in human platelets
124. Insulin-mimetic signalling of synthetic phosphoinositolglycans in isolated rat adipocytes
125. The role of glycosylphosphatidylinositol in signal transduction
126. Prostaglandylinositol cyclic phosphate, an antagonist to cyclic AMP
127. A model phosphatase 2C→phosphatase 1 activation cascade via dual control of inhibitor-1 (INH-1) and DARPP-32 dephosphorylation by two inositol glycan putative insulin mediators from beef liver